Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cadherin-23 is a type I transmembrane protein belonging to the cadherin superfamily, characterized by a large extracellular domain with 27 cadherin repeats and a cytoplasmic tail. It is a critical component of hair-cell tip links in the inner ear, where it mediates calcium-dependent cell–cell adhesion essential for mechanotransduction—the process by which hair cells convert mechanical sound vibrations into neural signals. The protein is also found in the retina, where it is required for normal photoreceptor cell function. Mutations in the CDH23 gene lead to non-syndromic prelingual hearing loss (DFNB12) and syndromic forms of deafness, particularly Usher syndrome type 1D, a leading cause of inherited deaf-blindness[2][3][4][5].
Not applicable; CDH23 is not a known direct drug target[5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin-23 (CDH23).